Expression of Wnt-1, beta-catenin and c-myc in ovarian epithelial tumor and its implication

Chinese Journal of Cancer Research

Volumn 20, Issue 1, 2008, Pages 73-76

  Lin, Xiao ^a   Hu, Zhuo Ying ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Beta catenin; c myc; Ovarian malignant epithelial tumors; Wnt 1

Indexed keywords

BETA CATENIN; MYC PROTEIN; WNT1 PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYSTADENOCARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PROTEIN EXPRESSION;

EID: 41149094079     PISSN: 10009604     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11670-008-0073-5     Document Type: Article

References (15)

1. Kolligs FT, Nieman MT, Winer I, et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation [J]. Cancer Cell 2002; 1:145-55.
2. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the pathway [J]. Oncogene 2006; 25:7531-7.
3. Herbst A, Kolligs FT, Wnt signaling as a therapentic target for cancer [J]. Methods Mol Biol 2007; 361:63-91.
4. Zhang MJ, Wang Q, Wang YH, et al. Immunohistochemical detection and clinical significance of beta-catenin expression in human colorectal cancer [J]. Acad J Sec Mil Med Univ (in Chin) 2000; 21:239-41.
5. Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues [J]. Hum Pathol 1990; 21:607-12.
6. Rhee CS, Sen M, Lu D, et al. Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas [J]. 2002; 21:6598-605.
7. Meirmanov S, Nakashima M, Rogounovitch T, et al. Small cell carcinoma of the endometrium: report of a case with analysis of Wnt/beta-catenin pathway [J]. Pathol Res Pract 2003; 199:551-8.
8. Moreno-Bueno G, Gamallo C, Pérez-Grallego L, et al. beta-catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas [J]. Diagn Mol Pathol 2001; 10:116-22.
9. Wu R, Zhai Y, Fearon ER, et al. Diverso mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas [J]. Cancer Res 2001; 61:8247-55.
10. Tanyi J, Pay A, Rigo J, et al. Mutation analysis of the beta-catenin gene in epithelial carcinomas of the ovaries [J]. Orv Hetil 2000; 141:1115-9.
11. Ryan KM, Birin CD. Myc oncogenes: the enigmatic family [J]. Biochem J 1996; 314:713-21.
12. He TC, Sparks AB, Rago C, et al. Identification of c-myc as a target of the APC pathway [J]. Science 1998; 281:1509-12.
13. Dimova I, Raitcheva S, Dimitrov R. et al. Correlations between c-myc gene copy-number and clinicopathological parameters of ovarian tumours [J]. Eur J Cancer 2006; 42:674-9.
14. Chen CH, Shen J, Lee WJ, et al. Overexpression of cyclin Dl and c-myc gene products in human primary epithelial ovarian cancer [J]. Int J Gynecol Cancer 2005; 15:878-83.
15. Iba T, Kigawa J, Kanamori Y, et al. Expression of the c-myc gene as a predictor of chrmotherapy response and a prognostic factor in patients with ovarian cancer [J]. Cancer Sci 2004; 95:418-23.